Jaguar Health shares climbed 33.19% as pediatric crofelemer patients entered an extension phase. A planned Series R conversion on November 2, 2026, could add to the share count as the company faces cash pressure.
Jaguar Health set October 13 as the record date for its Series R preferred-stock dividend and scheduled distribution for October 15. Each common share held on the record date entitles its holder to one Series R Convertible Preferred Stock share, according to the 8-K filing. The Series R shares are scheduled to convert into common stock on November 2, 2026, which could dilute existing shareholders. Jaguar is also weighing strategic alternatives. Its rare-disease program offers a longer-term potential catalyst.
All randomized pediatric patients in Jaguar's pivotal microvillus inclusion disease (MVID) crossover trial have entered a single-blind extension and are receiving crofelemer. Jaguar is targeting a New Drug Application filing around mid-2027. The company says it remains focused on developing oral crofelemer as an adjunct to parenteral support for rare intestinal-failure conditions, including MVID and short bowel syndrome with intestinal failure (SBS-IF), according to its official company release. That target gives investors a date to watch, but it does not guarantee a filing or regulatory approval.
Jaguar registered 2,325,000 Series R preferred shares for the dividend. Separate dividend rights also cover warrants for up to 142,535 common shares.
Progress is not proof. The trial's next phase shows the study is moving forward, but it does not show that crofelemer will succeed or reach the market.
Jaguar and its Napo unit have also cited early MVID and SBS-IF results. They reported durable reductions in patients' need for parenteral support, along with tolerability. Management has discussed the possibility of Breakthrough Therapy Designation and non-dilutive funding. Those discussions do not establish that the company will receive a designation or new funding. The available information gives no quantified treatment effect.
The adult program has a later timeline. Napo's abstract on crofelemer powder for adults with SBS-IF was accepted for ACG 2026. The company has guided to Phase 2 data in the second half of 2027. Those events could add information about the intestinal-failure program, but they are future catalysts, not clinical outcomes already in hand.
The Series R terms were set out in a separate Certificate of Designation filed in Delaware on October 2, 2026. The document establishes a 19.99% beneficial-ownership limit and an aggregate conversion cap of 11,625,000 common shares, subject to adjustment.
JAGX's trading history shows how fast expectations can shift. In mid-September 2026, the stock rose from $0.23 to $34.46 in a few sessions. It then fell below $10 and into the mid-$4 range. After failing to hold the spike, it closed near $4.73. Recent five-minute trading showed swings of roughly $5.50 to $7. This is a volatile stock. The reported 33.19% gain is not a stable repricing.
The company's finances add to the risk. Jaguar has about $11.5 million in annual revenue and reported free cash flow of roughly negative $5.3 million last quarter. Its current ratio is near 0.7, and it has negative working capital. The available financial information also describes leverage as high. Investors are left to weigh whether Jaguar can fund development and operations without issuing more shares or finding outside support.
The Series R distribution raises a separate question about share supply. It is not a cash payment. The announced preferred shares are expected to convert into common stock on November 2, 2026, which may increase the common-share count. The filing sets an automatic conversion ratio of five common shares for each Series R share, subject to the stated ownership limit and aggregate cap. Conversion and issuance are scheduled, not confirmed as complete. Jaguar's review of strategic alternatives is also ongoing, but it does not confirm a transaction or restructuring. The mechanics differ from a cash distribution such as the one covered in VICI Properties.
Jaguar is also taking smaller commercial and cost steps. Neonorm Dog has launched on Amazon, and Chewy is a potential future outlet. The FDA has waived 2027 fees for Mytesi and Canalevia-CA1. These steps may create sales opportunities or lower specific costs, but the available information does not quantify their financial contribution. They do not remove the company's reported cash-flow pressure.
The trade-off is plain. Crofelemer has clinical and regulatory milestones ahead, while Jaguar has limited financial flexibility and a planned conversion that could dilute common shareholders. The 33.19% gain shows investor attention to those catalysts. It does not show that the balance-sheet risk has been solved. Investors can judge the story by verified trial progress and financing terms, not by a sudden price spike or the promise of a future milestone.
Convertible preferred stock can let a company distribute securities before converting them into common shares. After conversion, existing common shareholders may own a smaller percentage if the total share count rises. The planned November 2026 timing matters. JAGX has a clinical timetable, but its financing structure remains a central risk.
